218 related articles for article (PubMed ID: 17940834)
1. Synergistic antitumor effect of combined 5-fluorouracil (5-FU) with 5-chloro-2,4-dihydroxypyridine on 5-FU-resistant gastric cancer cells: possible role of a dihydropyrimidine dehydrogenase-independent mechanism.
Sasaki E; Tominaga K; Kuwamura H; Watanabe T; Fujiwara Y; Oshitani N; Higuchi K; Arakawa T
J Gastroenterol; 2007 Oct; 42(10):816-22. PubMed ID: 17940834
[TBL] [Abstract][Full Text] [Related]
2. Thymidylate synthetase (TS) genotype and TS/dihydropyrimidine dehydrogenase mRNA level as an indicator in determining chemosensitivity to 5-fluorouracil in advanced gastric carcinoma.
Toriumi F; Kubota T; Saikawa Y; Yoshida M; Otani Y; Watanabe M; Kumai K; Kitajima M
Anticancer Res; 2004; 24(4):2455-63. PubMed ID: 15330198
[TBL] [Abstract][Full Text] [Related]
3. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
4. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
[TBL] [Abstract][Full Text] [Related]
5. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.
Shirasaka T; Shimamato Y; Ohshimo H; Yamaguchi M; Kato T; Yonekura K; Fukushima M
Anticancer Drugs; 1996 Jul; 7(5):548-57. PubMed ID: 8862723
[TBL] [Abstract][Full Text] [Related]
6. Alteration of dihydropyrimidine dehydrogenase expression by IFN-alpha affects the antiproliferative effects of 5-fluorouracil in human hepatocellular carcinoma cells.
Oie S; Ono M; Fukushima H; Hosoi F; Yano H; Maruyama Y; Kojiro M; Terada T; Hirano K; Kuwano M; Yamada Y
Mol Cancer Ther; 2007 Aug; 6(8):2310-8. PubMed ID: 17699726
[TBL] [Abstract][Full Text] [Related]
7. Reduction of 5-fluorouracil (5-FU) gastrointestinal (GI) toxicity resulting from the protection of thymidylate synthase (TS) in GI tissue by repeated simultaneous administration of potassium oxonate (Oxo) in rats.
Yoshisue K; Hironaga K; Yamaguchi S; Yamamoto A; Nagayama S; Kawaguchi Y
Cancer Chemother Pharmacol; 2000; 46(1):51-6. PubMed ID: 10912578
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.
Ide H; Kikuchi E; Hasegawa M; Kozakai N; Kosaka T; Miyajima A; Oya M
BMC Cancer; 2012 Sep; 12():420. PubMed ID: 22998564
[TBL] [Abstract][Full Text] [Related]
9. Superior antitumour activity of S-1 in tumours with a high dihydropyrimidine dehydrogenase activity.
Fujiwara H; Terashima M; Irinoda T; Takagane A; Abe K; Nakaya T; Yonezawa H; Oyama K; Takahashi M; Saito K; Takechi T; Fukushima M; Shirasaka T
Eur J Cancer; 2003 Nov; 39(16):2387-94. PubMed ID: 14556932
[TBL] [Abstract][Full Text] [Related]
10. Effects of combined administration of DPD-inhibitory oral fluoropyrimidine, S-1, plus paclitaxel on gene expressions of fluoropyrimidine metabolism-related enzymes in human gastric xenografts.
Sakurai Y; Yoshida I; Kamoshida S; Inaba K; Isogaki J; Komori Y; Uyama I; Tsutsumi Y
Ann Surg Oncol; 2008 Aug; 15(8):2301-9. PubMed ID: 18506536
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of S-1, a novel oral fluorouracil antitumor drug, for a chronic renal failure patient maintained on hemodialysis.
Tominaga K; Higuchi K; Okazaki H; Suto R; Hamaguchi M; Tanigawa T; Sasaki E; Shiba M; Watanabe T; Fujiwara Y; Oshitani N; Matsumoto T; Arakawa T
Oncology; 2004; 66(5):358-64. PubMed ID: 15331922
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy with a thymidylate synthase-inhibiting vector and S-1 has effective antitumor activity against 5-FU-resistant tumors.
Kadota K; Huang CL; Liu D; Yokomise H; Haba R; Wada H
Int J Oncol; 2011 Feb; 38(2):355-63. PubMed ID: 21174056
[TBL] [Abstract][Full Text] [Related]
13. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion.
Uchida K; Hayashi K; Kuramochi H; Takasaki K
Int J Oncol; 2001 Aug; 19(2):341-6. PubMed ID: 11445849
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of 5-fluorouracil in elderly Japanese patients with cancer treated with S-1 (a combination of tegafur and dihydropyrimidine dehydrogenase inhibitor 5-chloro-2,4-dihydroxypyridine).
Fujita K; Nakayama H; Ichikawa W; Yamamoto W; Endo H; Nagashima F; Tanaka R; Miya T; Sunakawa Y; Yamashita K; Mizuno K; Ishida H; Araki K; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Hirose T; Sasaki Y
Drug Metab Dispos; 2009 Jul; 37(7):1375-7. PubMed ID: 19389859
[TBL] [Abstract][Full Text] [Related]
16. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer.
Fakhrejahani E; Miyamoto A; Tanigawa N
Cancer Chemother Pharmacol; 2007 Aug; 60(3):437-46. PubMed ID: 17377791
[TBL] [Abstract][Full Text] [Related]
17. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines.
Wada Y; Yoshida K; Suzuki T; Mizuiri H; Konishi K; Ukon K; Tanabe K; Sakata Y; Fukushima M
Int J Cancer; 2006 Aug; 119(4):783-91. PubMed ID: 16557585
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Takechi T; Fujioka A; Matsushima E; Fukushima M
Eur J Cancer; 2002 Jun; 38(9):1271-7. PubMed ID: 12044515
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic enhancement of S-1 with CPT-11 through down-regulation of thymidylate synthase in bladder cancer.
Ide H; Kikuchi E; Hasegawa M; Hattori S; Yasumizu Y; Miyajima A; Oya M
Cancer Med; 2013 Aug; 2(4):488-95. PubMed ID: 24156021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
